Theralase Technologies Inc. (TLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Theralase Technologies Inc. (TLT) has a cash flow conversion efficiency ratio of -0.180x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-1.23 Million ≈ $-889.90K USD) by net assets (CA$6.84 Million ≈ $4.95 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Theralase Technologies Inc. for the company's overall valuation and market capitalisation.
Theralase Technologies Inc. - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Theralase Technologies Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Theralase Technologies Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theralase Technologies Inc. ranked by their cash flow conversion efficiency. Explore TLT cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Metagenomi, Inc. Common Stock
NASDAQ:MGX
|
-0.173x |
|
Creas F&C Co.Ltd
KQ:110790
|
-0.010x |
|
Visang Educati
KO:100220
|
-0.040x |
|
Componenta Corp
HE:CTH1V
|
0.115x |
|
Appasia Bhd
KLSE:0119
|
-0.022x |
|
Highlight Communications AG
XETRA:HLG
|
-26.847x |
|
Sinher Technology Inc
TW:4999
|
0.012x |
|
Winner Group Enterprise Public Company Limited
BK:WINNER
|
-0.097x |
Annual Cash Flow Conversion Efficiency for Theralase Technologies Inc. (2001–2025)
The table below shows the annual cash flow conversion efficiency of Theralase Technologies Inc. from 2001 to 2025. View Theralase Technologies Inc. stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$1.78 Million ≈ $1.29 Million |
CA$-3.29 Million ≈ $-2.38 Million |
-1.848x | -14.88% |
| 2024-12-31 | CA$2.07 Million ≈ $1.50 Million |
CA$-3.33 Million ≈ $-2.41 Million |
-1.609x | +24.73% |
| 2023-12-31 | CA$1.91 Million ≈ $1.38 Million |
CA$-4.07 Million ≈ $-2.95 Million |
-2.137x | -28.78% |
| 2022-12-31 | CA$3.09 Million ≈ $2.24 Million |
CA$-5.13 Million ≈ $-3.71 Million |
-1.660x | -108.79% |
| 2021-12-31 | CA$5.07 Million ≈ $3.67 Million |
CA$-4.03 Million ≈ $-2.92 Million |
-0.795x | -63.83% |
| 2020-12-31 | CA$9.16 Million ≈ $6.63 Million |
CA$-4.45 Million ≈ $-3.22 Million |
-0.485x | -2.38% |
| 2019-12-31 | CA$13.86 Million ≈ $10.02 Million |
CA$-6.57 Million ≈ $-4.75 Million |
-0.474x | +61.07% |
| 2018-12-31 | CA$998.64K ≈ $722.40K |
CA$-1.22 Million ≈ $-879.39K |
-1.217x | +41.54% |
| 2017-12-31 | CA$2.05 Million ≈ $1.48 Million |
CA$-4.26 Million ≈ $-3.08 Million |
-2.082x | -142.84% |
| 2016-12-31 | CA$5.69 Million ≈ $4.12 Million |
CA$-4.88 Million ≈ $-3.53 Million |
-0.858x | -7.39% |
| 2015-12-31 | CA$6.32 Million ≈ $4.57 Million |
CA$-5.04 Million ≈ $-3.65 Million |
-0.799x | +27.19% |
| 2014-12-31 | CA$3.31 Million ≈ $2.39 Million |
CA$-3.63 Million ≈ $-2.62 Million |
-1.097x | -111.05% |
| 2013-12-31 | CA$1.76 Million ≈ $1.28 Million |
CA$-916.67K ≈ $-663.11K |
-0.520x | -105.54% |
| 2012-12-31 | CA$-64.73K ≈ $-46.82K |
CA$-606.72K ≈ $-438.89K |
9.373x | +405.21% |
| 2011-12-31 | CA$455.16K ≈ $329.25K |
CA$-1.40 Million ≈ $-1.01 Million |
-3.071x | -663.82% |
| 2010-12-31 | CA$2.53 Million ≈ $1.83 Million |
CA$-1.02 Million ≈ $-735.94K |
-0.402x | -3323.44% |
| 2009-12-31 | CA$3.49 Million ≈ $2.52 Million |
CA$-40.95K ≈ $-29.62K |
-0.012x | +92.02% |
| 2008-12-31 | CA$2.39 Million ≈ $1.73 Million |
CA$-351.19K ≈ $-254.05K |
-0.147x | -41.17% |
| 2007-12-31 | CA$3.37 Million ≈ $2.44 Million |
CA$-351.49K ≈ $-254.26K |
-0.104x | -1262.74% |
| 2006-12-31 | CA$3.37 Million ≈ $2.44 Million |
CA$-25.78K ≈ $-18.65K |
-0.008x | -130.39% |
| 2005-12-31 | CA$3.39 Million ≈ $2.45 Million |
CA$85.33K ≈ $61.73K |
0.025x | +130.40% |
| 2004-12-31 | CA$1.05 Million ≈ $762.12K |
CA$-87.23K ≈ $-63.10K |
-0.083x | +82.82% |
| 2003-12-31 | CA$399.21K ≈ $288.78K |
CA$-192.39K ≈ $-139.17K |
-0.482x | +13.24% |
| 2002-12-31 | CA$87.35K ≈ $63.19K |
CA$-48.52K ≈ $-35.10K |
-0.555x | +7.87% |
| 2001-12-31 | CA$137.03K ≈ $99.13K |
CA$-82.62K ≈ $-59.76K |
-0.603x | -- |
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form … Read more